Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Journal Volume
19
Journal Issue
2
Pages
297
Date Issued
2024-02-24
Author(s)
Reck, Martin
Barlesi, Fabrice
Westeel, Virginie
Felip, Enriqueta
Özgüroğlu, Mustafa
Dols, Manuel Cobo
Sullivan, Richard
Kowalski, Dariusz M
Andric, Zoran
Lee, Dae Ho
Sezer, Ahmet
Hu, Ping
Wang, XiaoZhe
von Heydebreck, Anja
Jacob, Natalia
Mehr, Keyvan Tadjalli
Park, Keunchil
Abstract
We report the primary analysis from JAVELIN Lung 100, a phase 3 trial comparing avelumab (anti-programmed death-ligand 1 [PD-L1]) versus platinum-based doublet chemotherapy as first-line treatment for PD-L1-positive (+) advanced NSCLC.
Subjects
Avelumab; Chemotherapy; First-line; Non–small cell lung cancer; Phase 3
SDGs
Type
journal article